U.S. markets open in 7 hours 53 minutes
  • S&P Futures

    4,129.75
    +22.75 (+0.55%)
     
  • Dow Futures

    34,106.00
    +168.00 (+0.50%)
     
  • Nasdaq Futures

    13,191.00
    +90.75 (+0.69%)
     
  • Russell 2000 Futures

    2,183.50
    +14.90 (+0.69%)
     
  • Crude Oil

    63.81
    -0.01 (-0.02%)
     
  • Gold

    1,823.30
    -0.70 (-0.04%)
     
  • Silver

    27.06
    -0.00 (-0.01%)
     
  • EUR/USD

    1.2093
    +0.0009 (+0.07%)
     
  • 10-Yr Bond

    1.6680
    0.0000 (0.00%)
     
  • Vix

    23.13
    -4.46 (-16.17%)
     
  • GBP/USD

    1.4050
    -0.0001 (-0.01%)
     
  • USD/JPY

    109.5000
    +0.0660 (+0.06%)
     
  • BTC-USD

    49,229.50
    -1,791.32 (-3.51%)
     
  • CMC Crypto 200

    1,357.68
    -30.22 (-2.18%)
     
  • FTSE 100

    6,963.33
    -41.30 (-0.59%)
     
  • Nikkei 225

    28,114.21
    +666.20 (+2.43%)
     

Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action - iRobot Corporation (IRBT), Zendesk, Inc. (ZEN) & Zynerba Pharmaceuticals, Inc. (ZYNE)

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / November 25, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

iRobot Corporation (NASDAQ:IRBT)

Class Period: November 21, 2016 - October 22, 2019

Deadline: December 23, 2019
For more info: www.bgandg.com/irbt

The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) iRobot's explosive growth was not based on increased demand, expanding margins, and product innovations, as it claimed, but rather based on channel stuffing; (2) the Company attempted to conceal its actions by acquiring its distributors in Europe and Asia; (3) these acquisitions were designed to clean up the company's global inventory and mask falling demand; and (4) as a result, iRobot's public statements were materially false and misleading at all relevant times.

Zendesk, Inc. (NASDAQ:ZEN)

Class Period: February 6, 2019 - October 1, 2019

Deadline: December 23, 2019
For more info: www.bgandg.com/zen

The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Zendesk's clients had been subject to data breaches dating back to 2016; (2) Zendesk was experiencing slowing demand for its SaaS offerings, particularly in Germany, the U.K. and Australia, due in large part to political uncertainty and China trade issues; (3) for the forgoing reasons, Zendesk's business metrics and financial prospects were not as strong as represented during the Class Period; and (4) as a result, Zendesk's public statements were materially false and misleading at all relevant times.

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE)

Class Period: March 11, 2019 - September 17, 2019

Deadline: December 23, 2019
For more info: www.bgandg.com/zyne

The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Zygel was proving unsafe and not well-tolerated in the BELIEVE 1 Trial; (2) the foregoing created a foreseeable, heightened risk that Zynerba would fail to secure the necessary regulatory approvals for commercializing Zygel for the treatment of DEE in children and adolescents; and (3) as a result, the Company's public statements were materially false and misleading at all relevant times.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/567915/Bronstein-Gewirtz-Grossman-LLC-Reminds-Investors-of-Class-Action--iRobot-Corporation-IRBT-Zendesk-Inc-ZEN-Zynerba-Pharmaceuticals-Inc-ZYNE